Nature Reviews Neurology

Article	Citations
Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?	1209
Technology of deep brain stimulation: current status and future directions	327
Protein transmission in neurodegenerative disease	323
Lifting the mask on neurological manifestations of COVID-19	308
Recovery from disorders of consciousness: mechanisms, prognosis and emerging therapies	262
Applications of machine learning to diagnosis and treatment of neurodegenerative diseases	249
Parkinson disease and the immune system — associations, mechanisms and therapeutics	247
Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities	245
Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: challenges and opportunities	217
Maternal immune activation and neuroinflammation in human neurodevelopmental disorders	214
Applications of focused ultrasound in the brain: from thermoablation to drug delivery	200
Blood GFAP as an emerging biomarker in brain and spinal cord disorders	194
Diagnosis and management of migraine in ten steps	183
Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease	166
Prodromal Parkinson disease subtypes — key to understanding heterogeneity	166
Multilevel omics for the discovery of biomarkers and therapeutic targets for stroke	163
Peripheral and central immune system crosstalk in Alzheimer disease — a research prospectus	160
Complement in neurological disorders and emerging complement-targeted therapeutics	154
Improving clinical trial outcomes in amyotrophic lateral sclerosis	146
Cycles in epilepsy	140
Developing the ATX(N) classification for use across the Alzheimer disease continuum	137
The effects of the COVID-19 pandemic on people with dementia	130
Neurological infection with SARS-CoV-2 — the story so far	130
GAD antibodies in neurological disorders — insights and challenges	127
The polygenic architecture of schizophrenia — rethinking pathogenesis and nosology	118

An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders	115
B cells in multiple sclerosis — from targeted depletion to immune reconstitution therapies	108
Post-traumatic stress disorder: clinical and translational neuroscience from cells to circuits	104
Inflammation in acquired hydrocephalus: pathogenic mechanisms and therapeutic targets	102
Advances in local therapy for glioblastoma — taking the fight to the tumour	102
Management of brain metastases according to molecular subtypes	100
Treatment and management of cognitive dysfunction in patients with multiple sclerosis	100
The human connectome in Alzheimer disease — relationship to biomarkers and genetics	98
Virtual reality in research and rehabilitation of gait and balance in Parkinson disease	97
Drug repositioning and repurposing for Alzheimer disease	96
Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours	95
Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility	94
The microbiome–gut–brain axis in Parkinson disease — from basic research to the clinic	93
Stroke in Africa: profile, progress, prospects and priorities	92
Do infections have a role in the pathogenesis of Alzheimer disease?	91
MicroRNAs as regulators of brain function and targets for treatment of epilepsy	89
Circadian rhythms in neurodegenerative disorders	87
CRISPR-based functional genomics for neurological disease	86
Metagenomics for neurological infections — expanding our imagination	86
Hypomyelinating leukodystrophies — unravelling myelin biology	82
Synaptic degeneration in Alzheimer disease	81
Spinal muscular atrophy — insights and challenges in the treatment era	79
Status of peripheral sodium channel blockers for non-addictive pain treatment	79
Non-neuronal cells in amyotrophic lateral sclerosis — from pathogenesis to biomarkers	75
The neuroanatomical–functional paradox in spinal cord injury	74
Development of disease-modifying drugs for frontotemporal dementia spectrum disorders	71
The inter-relationship between delirium and dementia: the importance of delirium prevention	69
Apparent changes in the epidemiology and severity of multiple sclerosis	69
The metabolic basis of epilepsy	67
The importance of ongoing international surveillance for Creutzfeldt–Jakob disease	66
Aducanumab and the FDA — where are we now?	66
Can we learn lessons from the FDA’s approval of aducanumab?	64
The case for low-level BACE1 inhibition for the prevention of Alzheimer disease	63
Lung innervation in the eye of a cytokine storm: neuroimmune interactions and COVID-19	60
Pharmacological brain cytoprotection in acute ischaemic stroke — renewed hope in the reperfusion era	59
White matter injury in infants with intraventricular haemorrhage: mechanisms and therapies	59
Impact of predictive, preventive and precision medicine strategies in epilepsy	58
Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis	57
Amyloid-β: a potential link between epilepsy and cognitive decline	56
Hope for patients with neuromyelitis optica spectrum disorders — from mechanisms to trials	56
Psychosis in Alzheimer disease — mechanisms, genetics and therapeutic opportunities	56
Gene–environment interactions in Alzheimer disease: the emerging role of epigenetics	53
Neurological immunotherapy in the era of COVID-19 — looking for consensus in the literature	53
International consensus recommendations on the diagnostic work-up for malformations of cortical development	53
Identification of clinically relevant biomarkers of epileptogenesis — a strategic roadmap	53
The role of glial cells in multiple sclerosis disease progression	52
Neurobehavioural comorbidities of epilepsy: towards a network-based precision taxonomy	51
Nodes of Ranvier during development and repair in the CNS	51
The multiple sclerosis prodrome	49
Functional roles of reactive astrocytes in neuroinflammation and neurodegeneration	49

Alzheimer disease in African American individuals: increased incidence or not enough data?	49
Human cerebral organoids — a new tool for clinical neurology research	47
The B cell immunobiology that underlies CNS autoantibody-mediated diseases	46
Mind the gap: from neurons to networks to outcomes in multiple sclerosis	45
Hormonal influences in migraine — interactions of oestrogen, oxytocin and CGRP	45
Epstein–Barr virus as a leading cause of multiple sclerosis: mechanisms and implications	45
Changing demography and the challenge of dementia in India	44
Astrocytes in the initiation and progression of epilepsy	44
Multimodal brain and retinal imaging of dopaminergic degeneration in Parkinson disease	44
The role of the gut microbiota in multiple sclerosis	43
Global epidemiology of migraine and its implications for public health and health policy	42
Artificial intelligence for decision support in acute stroke — current roles and potential	42
Autonomic manifestations of epilepsy: emerging pathways to sudden death?	41
Early-stage Alzheimer disease: getting trial-ready	41
Cluster headache pathophysiology — insights from current and emerging treatments	41
The approval of Aduhelm risks eroding public trust in Alzheimer research and the FDA	40
Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies	40
MRI biomarkers in neuro-oncology	40
Sex and gender in neurodevelopmental conditions	35
Perinatal stroke: mapping and modulating developmental plasticity	34
Nuclear pore complexes — a doorway to neural injury in neurodegeneration	33
Why won’t it stop? The dynamics of benzodiazepine resistance in status epilepticus	31
Single-cell and spatial transcriptomics: deciphering brain complexity in health and disease	31
COVID-19 and management of neuroimmunological disorders	31
Cognitive adverse effects of chemotherapy and immunotherapy: are interventions within reach?	31
Refining oxytocin therapy for autism: context is key	30
Drug-resistant epilepsy — time to target mechanisms	30
Dissecting the complexities of Alzheimer disease with in vitro models of the human brain	30
Genetics of common cerebral small vessel disease	29
Rapidly progressive dementias — aetiologies, diagnosis and management	29
Applying genomic and transcriptomic advances to mitochondrial medicine	29
Guillain–Barré syndrome in low-income and middle-income countries: challenges and prospects	28
The neurovascular unit and systemic biology in stroke — implications for translation and treatment	27
Social determinants of health in multiple sclerosis	27
hiPSCs for predictive modelling of neurodegenerative diseases: dreaming the possible	27
Multifaceted microglia — key players in primary brain tumour heterogeneity	27
Vaccination and immunotherapies in neuroimmunological diseases	27
Bruton tyrosine kinase inhibitors for multiple sclerosis	26
Positron emission tomography in multiple sclerosis — straight to the target	26
Lesions without symptoms: understanding resilience to Alzheimer disease neuropathological changes	26
Emerging therapies to target CNS pathophysiology in multiple sclerosis	25
Genetic testing in dementia — utility and clinical strategies	25
Review and update of the concept of embolic stroke of undetermined source	25
‘Concussion’ is not a true diagnosis	25
Prospective memory impairment in neurological disorders: implications and management	24
Lecanemab trial in AD brings hope but requires greater clarity	22
New insights into the neurological effects of COVID-19	22
From the prodromal stage of multiple sclerosis to disease prevention	22
Closing the loop for patients with Parkinson disease: where are we?	20
Neuropsychology’s race problem does not begin or end with demographically adjusted norms	20
Inequities in neurology amplified by the COVID-19 pandemic	20
Neurological telemedicine in the COVID-19 era	20
Neurogenetic disorders across the lifespan: from aberrant development to degeneration	19
Facing the urgency of therapies for progressive MS — a Progressive MS Alliance proposal	18
Zoonotic and vector-borne parasites and epilepsy in low-income and middle-income countries	18
Gene therapy for primary mitochondrial diseases: experimental advances and clinical challenges	18
Headache in people with epilepsy	18
Cognitive impairment and World Trade Centre-related exposures	18
Inflammation in multiple sclerosis: consequences for remyelination and disease progression	17
A global view of the genetic basis of Alzheimer disease	17
The role of astrocytic α7 nicotinic acetylcholine receptors in Alzheimer disease	17
Functional brain networks in the evaluation of patients with neurodegenerative disorders	17
Genetic generalized epilepsies in adults — challenging assumptions and dogmas	17
Counting the neurological cost of COVID-19	17
Maximizing treatment efficacy through patient stratification in neuropathic pain trials	17
Neuroprognostication: a conceptual framework	17
SARS-CoV-2 detected in olfactory neurons	16
Neurodegenerative diseases associated with non-coding CGG tandem repeat expansions	16
Epigenetic genes and epilepsy — emerging mechanisms and clinical applications	15
The childhood migraine syndrome	15
Global synergistic actions to improve brain health for human development	15
A cultural approach to dementia — insights from US Latino and other minoritized groups	15
Exosomal α-synuclein as a biomarker for Parkinson disease	14
Towards treating progressive multiple sclerosis	14
Pathogenic autoantibodies in multiple sclerosis — from a simple idea to a complex concept	13
Isoform-dependent APOE secretion modulates neuroinflammation	13
Aspirin and ibuprofen could lower risk of LRRK2 Parkinson disease	12
Beyond recanalization — a call for action in acute stroke	12
Why functional neurological disorder is not feigning or malingering	12
The noradrenergic subtype of Parkinson disease: from animal models to clinical practice	12

Spinal muscular atrophy — the dawning of a new era	12
Adaptive and maladaptive myelination in health and disease	12
Recessive cerebellar and afferent ataxias — clinical challenges and future directions	12
The challenges of anti-tau therapeutics in Alzheimer disease	12
Cognitive impairment in people living with HIV: consensus recommendations for a new approach	11
Endovascular stroke treatment during the COVID-19 pandemic	10
Cell-based therapies for neurological disorders — the bioreactor hypothesis	10
The search for Alzheimer disease therapeutics — same targets, better trials?	10
Origins and immunopathogenesis of autoimmune central nervous system disorders	9
Towards a global view of multiple sclerosis genetics	9
Brain changes after COVID-19 — how concerned should we be?	9
Fundamental mechanistic insights from rare but paradigmatic neuroimmunological diseases	9
Pain-resolving immune mechanisms in neuropathic pain	9
Viral pathogens increase risk of neurodegenerative disease	8
Standardization and digitization of clinical data in multiple sclerosis	8
The expanding role of MRI in neuromuscular disorders	8
The missing X factor in Alzheimer disease	8
New insights into very-late-onset myasthenia gravis	8
Defining traumatic encephalopathy syndrome — advances and challenges	8
T cells step up after SARS-CoV-2 vaccination with B cell depletion	8
Neurological soft signs predict outcomes in schizophrenia	8
Facioscapulohumeral muscular dystrophy: the road to targeted therapies	7
Prospects for gene replacement therapies in amyotrophic lateral sclerosis	7
Getting specific: targeting Fc receptors in myasthenia gravis	7
Tau-targeting therapies for Alzheimer disease: current status and future directions	7
NLRP3 inflammasome activity as biomarker for primary progressive multiple sclerosis	7
Disease-modifying therapy aids cognition in multiple sclerosis	7
Cohort-guided insights into gene–environment interactions in autism spectrum disorders	7
The African Stroke Organization — a new dawn for stroke in Africa	7
Genome-wide analysis furthers decoding of Alzheimer disease genetics	7
Mitochondrial dysfunction manifests in the early stages of Alzheimer disease	6
SARS-CoV-2 and the brain to be studied long-term	6
Changes in brain drainage systems are linked to Parkinson disease	6
Ventricular enlargement caused by aducanumab	6
Mechanisms underlying phenotypic variation in neurogenetic disorders	6
Digital assessment at home — mPower against Parkinson disease	6
The amyotrophic lateral sclerosis exposome: recent advances and future directions	6
Making headway — a role for CGRP in post-traumatic headache	6
Towards improving care for disorders of consciousness	6
Neurological manifestations of rhino-oculo-cerebral mucormycosis in the COVID-19 era	6
The Parkinson disease connectome — insights from new imaging studies	5
Elevated risk of COVID-19 in people with dementia	5
Huntington disease alters early neurodevelopment	5
Exosomal microRNA is promising biomarker in PD	5
First trials test targeting of α-synuclein for Parkinson disease	5
Bidirectional brain–computer interface aids robotic arm control	5
Aberrant protein networks in Alzheimer disease	5
EAN VIRTUAL 2020 — THE LARGEST NEUROLOGY CONFERENCE IN HISTORY	5
Risk–benefit analysis of COVID-19 vaccines — a neurological perspective	5
Disease modification is not all — we need symptomatic therapies for Alzheimer disease	5
Combining biomarkers to profile multiple sclerosis patients	5
Neural cell state shifts and fate loss in ageing and age-related diseases	5
Potassium channel openers — novel triggers of aura and migraine	5
Lessons from lockdown — behavioural interventions in migraine	5
Pathogenetic insights into young-onset Parkinson disease	4
Remyelination therapy for demyelinating disease	4
Nutritional and metabolic factors in amyotrophic lateral sclerosis	4
Trigeminal neuralgia linked to demyelination in multiple sclerosis	4
Publisher Correction: Peripheral and central immune system crosstalk in Alzheimer disease — a research prospectus	4
Meningeal lymphatic flow slows after mild traumatic brain injury	4
Barriers to implementation of evidence into clinical practice in low-resource settings	4
Single-cell transcriptomics reveals neuroinflammation in severe COVID-19	4
Disentangling placebo effects in the treatment of migraine	4
Implications of research that excludes under-served populations	4
Does antiherpetic antiviral therapy reduce the risk of dementia?	4
Development and implementation of new diagnostic technologies in neurology	4
From precision diagnosis to precision treatment in epilepsy	4
Functional neurological disorder and placebo and nocebo effects: shared mechanisms	4
VEGFA mediates blood–brain barrier disruption in Parkinson disease	4
Prion protein — mediator of toxicity in multiple proteinopathies	4
Molecular biomarkers for vascular cognitive impairment and dementia	4
Comparative effectiveness of rituximab in multiple sclerosis	3
Dense-core plaques could be beneficial in AD	3
Brain organoids shed light on APOE genotype and Alzheimer disease pathology	3
Reactive astrocyte biomarkers mirror Alzheimer disease pathology	3
Parkinson disease risk variants in East Asian populations	3
Rethink the classical view of cerebrospinal fluid production	3
Slowly expanding lesions are linked to multiple sclerosis progression	3
Neuroimmune interactions and COVID-19 in lung transplant recipients	3
Assessing prospective memory beyond experimental tasks	3
Neuropsychiatric symptoms in AD: the search for mechanisms	3
Influence of amyloid-β on tau spread in Alzheimer disease explained	3
Neuropsychological impairment in amyotrophic lateral sclerosis–frontotemporal spectrum disorder	3
Is it time for genetic modifiers to predict prognosis in Duchenne muscular dystrophy?	3
Extracellular protein homeostasis in neurodegenerative diseases	3
α-Synuclein-activated microglia are implicated in PD pathogenesis	3
TREM2 activation promotes remyelination	3
The translational potential of cholesterol-based therapies for neurological disease	3
Closer to a blood test for Alzheimer disease	3
Targeting connexin hemichannels to treat temporal lobe epilepsy	2
APOE4 provokes tau aggregation via inhibition of noradrenaline transport	2
Exosomal microRNAs may aid differential diagnosis of movement disorders	2
COVID-19 and the neurological disease therapeutic pipeline	2
Treating epilepsy in forcibly displaced persons: timely, necessary, affordable	2
Potential gene therapy for FTD	2